Mouse xenograft models for drug discovery in pancreatic cancer

Belen Rubio-Viqueira, Manuel Hidalgo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

It is estimated that the development of a new anticancer agent costs US $800-1,000 million and takes over a decade between conception and approval. However, 90% of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models. This raises serious concerns whether such models are predictive of drug efficacy in humans, supporting the development of alternative approaches. Furthermore, a general transition has been observed from the empirical drug screening of cytotoxic agents against uncharacterized tumor models to target-orientated drug screening of agents with defined mechanisms of action. New approaches to anticancer drug development involve the molecular characterization of models along with an appreciation of the pharmacodynamic and pharmacokinetic properties of the tested drug. This chapter focuses on the classical and new preclinical screening models and techniques for anticancer drug development.

Original languageEnglish (US)
Title of host publicationDrug Discovery in Pancreatic Cancer
Subtitle of host publicationModels and Techniques
PublisherSpringer New York
Pages29-49
Number of pages21
ISBN (Print)9781441911599
DOIs
StatePublished - Dec 1 2010

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Rubio-Viqueira, B., & Hidalgo, M. (2010). Mouse xenograft models for drug discovery in pancreatic cancer. In Drug Discovery in Pancreatic Cancer: Models and Techniques (pp. 29-49). Springer New York. https://doi.org/10.1007/978-1-4419-1160-5_2